398 | LACUTAMAB IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MYCOSIS FUNGOIDES: LONG TERM FOLLOW‐UP AND TRANSLATIONAL DATA FROM THE TELLOMAK PHASE 2 TRIAL | Publicación